Amgen To Present At The 2021 Jefferies Healthcare Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/1/2026
- Wall St set to slip as US-Iran tensions cloud start to second half
- Oil falls as markets await outcome of Iran-US talks, US stocks data
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Dollar firm at 1-year highs as Euro Inflation cools; yen in Intervention zone
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- S&P 500, Nasdaq register best quarter since 2020 despite Iran war
- Cantor Fitzgerald Starts Forward Industries (FWDI) at Overweight
- DISH DBS files prepackaged chapter 11 to repay debt, wind down wireless
- NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
- Boeing commercial jet deliveries and production disrupted by widespread IT outage - Air Current
Amgen (AMGN) PT Raised to $272 at Oppenheimer
June 1, 2021 3:29 PM EDTOppenheimer analyst Jay Olson raised the price target on Amgen (NASDAQ: AMGN) to $272.00 (from $270.00) while maintaining an Outperform rating.
The analyst commented, "AMGN announced FDA approval of Lumakras ~2.5 months ahead of the 8/16 PDUFA. The approval marks the first KRAS G12C... More
